Accelerating Drug Discovery for FTD
Through this program, AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) seek to accelerate drug discovery by supporting research focused on the identification and preclinical testing of promising compounds.
Priority areas for this program include:
- Development and testing of high-throughput screening assays.
- Identification and testing of potentially disease-modifying therapies, including:
- Medicinal chemistry.
- Pharmacokinetic/pharmacodynamics studies.
- Testing of novel lead compounds, biologics, or repurposed drugs in a relevant animal model.
- Development and/or characterization of new model organisms or cellular models to support drug discovery efforts.
- Duration: 1 year, with the possibility of follow-on funding.
- Amount of award (USD): Typically $100,000 – 150,000.
- Application of funds: Direct costs only.
- Additional Information: Visit the ADDF website for additional information.
Who can apply?
- Investigators at not-for-profit academic and medical research institutions
- For-profit biotechnology companies that demonstrate a clear need for non-profit funding, both public and private (note that funding to biotechnology companies is typically made as a program-related investment)
- S. and international investigators
Timeline — 2017 Awards
LOIs are reviewed on a rolling basis and can be submitted at any time prior to the deadline.
Applications are reviewed by ADDF and an external Scientific Review Committee, including members of the AFTD Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF’s Business Advisory Board.
To further discuss scientific or financial aspects of proposals, please contact:
- Lauren Friedman, PhD, Acting Director for Scientific Affairs, ADDF
- Nadine Tatton, PhD, Scientific Director, AFTD
Phone: 267-758-8644 / Email: email@example.com
For more information about the application process, please contact:
- Grants and Contracts Team, ADDF
Phone: 212-901-7998 / Email: firstname.lastname@example.org